Breast cancer

14 December 2009

Chemotherapy boosts breast cancer survival: study

This article has not necessarily been edited by Health24.

Chemotherapy helps improve breast cancer survival in post-menopausal women, adding to a long-standing debate about how best to treat these women, US researchers said on Thursday.

A gene-based test called Oncotype DX made by Genomic Health Inc may help identify a small group of women who are not likely to benefit from chemotherapy, a second study found.

The main study proves that adding chemotherapy to treatment with the estrogen-blocking drug tamoxifen can help prevent cancer from coming back in women with estrogen-receptor positive breast cancers, the most common kind in which a hormone is driving the cancer.

"We have a survival benefit that lasts for a very long time ... for women who got both modalities of treatment versus women who just got tamoxifen," said Dr. Kathy Albain of Loyola University Health System in Maywood, Illinois.She presented findings from both studies at the American Association for Cancer Research San Antonio Breast Cancer Symposium.

"It is considered a landmark study in the clinical trials literature because it is the only one really demonstrating the survival advantage of chemotherapy added to tamoxifen," Albain said in a telephone interview. "Up until this trial, studies adding common chemotherapy drugs to tamoxifen or tamoxifen alone were essentially negative.

"For the study, the team followed nearly 1,500 post-menopausal women with estrogen-receptor positive breast cancers that had spread to at least one lymph node. Some of the women got both tamoxifen and a chemotherapy drug known as anthracycline, and some got tamoxifen alone.

The team found that the women who got the chemotherapy were 24 percent less likely to have their cancer come back.

They were also 17 percent less likely to die during the 10-year study period, but this finding was just shy of meeting statistical significance.The team also found that giving tamoxifen after chemotherapy ended instead of during chemotherapy improved a woman's survival chances.

In a second study led by Albain, published in the journal Lancet Oncology, the team evaluated whether the Oncotype DX test can predict which women would benefit from chemotherapy.The test examines 21 genes from a tumor sample to see how active they are, and produces a score that predicts chemotherapy benefit. It is most commonly used in women with estrogen-fed tumors whose cancer has not spread to a lymph node.

But Albain's study suggests it may also be useful in identifying women whose tumors had spread that would not benefit from chemotherapy.

Albain said a large clinical trial is getting started that will confirm whether the test is effective, but that will be expensive and take many years.Meanwhile, she said, some doctors like herself plan to use the test on certain patients to give them more choices about their breast cancer treatment options. (Reuters Health, December 2009)


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules